Patents by Inventor Alexandre Fontayne
Alexandre Fontayne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230265155Abstract: Disclosed is a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.Type: ApplicationFiled: March 31, 2023Publication date: August 24, 2023Inventors: Celine MONNET, Philippe MONDON, Alexandre FONTAYNE, Christophe DE ROMEUF
-
Patent number: 11649271Abstract: Disclosed is to a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.Type: GrantFiled: May 6, 2016Date of Patent: May 16, 2023Assignee: LABORATOIRE FRANÇ-̧AIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Celine Monnet, Philippe Mondon, Alexandre Fontayne, Christophe De Romeuf
-
Patent number: 11091552Abstract: A specific binding molecule is provided which binds to galectin-3 protein, methods of their production and methods of use.Type: GrantFiled: October 5, 2018Date of Patent: August 17, 2021Assignees: LABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE BORDEAUXInventors: Alexandre Fontayne, Philippe Mondon, Jeanny Laroche-Traineau, Marie-Josée Jacobin-Valat, Martine Cérutti, Gisèle Clofent-Sanchez, Cyril Lorenzato, Audrey Hémadou
-
Publication number: 20210079101Abstract: A specific binding molecule is provided which binds to galectin-3 protein, methods of their production and methods of use.Type: ApplicationFiled: October 5, 2018Publication date: March 18, 2021Inventors: Alexandre FONTAYNE, Philippe MONDON, Jeanny LAROCHE-TRAINEAU, Marie-Josée JACOBIN-VALAT, Martine CÉRUTTI, Gisèle CLOFENT-SANCHEZ, Cyril LORENZATO, Audrey HÉMADOU
-
Publication number: 20200277385Abstract: The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.Type: ApplicationFiled: February 24, 2020Publication date: September 3, 2020Applicant: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Nathalie FOURNIER, Alexandre FONTAYNE, Christophe de ROMEUF
-
Patent number: 10611843Abstract: The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.Type: GrantFiled: March 31, 2016Date of Patent: April 7, 2020Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Nathalie Fournier, Alexandre Fontayne, Christophe de Romeuf
-
Publication number: 20180355034Abstract: The present invention relates to the use of antibody Fc fragments in the treatment of autoimmune and/or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments having a modified affinity for at least one of the Fc receptors (FcR), particularly an increased affinity to FcRn.Type: ApplicationFiled: July 6, 2016Publication date: December 13, 2018Applicant: Laboratoire Français du Fractionnement et des BiotechnologiesInventors: Philippe Mondon, Céline Monnet-Mars, Alexandre Fontayne, Christophe De Romeuf, Abdessatar Chtourou
-
Publication number: 20180086834Abstract: The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.Type: ApplicationFiled: March 31, 2016Publication date: March 29, 2018Applicant: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Nathalie FOURNIER, Alexandre FONTAYNE, Christophe de ROMEUF
-
Publication number: 20180030111Abstract: Disclosed is to a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.Type: ApplicationFiled: May 6, 2016Publication date: February 1, 2018Inventors: Celine MONNET, Philippe MONDON, Alexandre FONTAYNE, Christophe DE ROMEUF
-
Publication number: 20170260254Abstract: The present invention relates to a method for increasing the sialylation of an Fc fragment, including a mutation step of at least one amino acid selected from among the amino acids in positions 240 to 243, 258 to 267 and 290 to 305 of the Fc fragment, the numbering being that of the EU index or equivalent in Kabat. The present invention also relates to a method for producing a variant of a parent polypeptide including an Fc fragment, the variant having improved sialylation of the Fc fragment relatively to the parent polypeptide, which includes a mutation step of at least one amino acid selected from among the amino acids in positions 240 to 243, 258 to 267 and 290 to 305 of the Fc fragment, the numbering being that of the EU index or equivalent in Kabat.Type: ApplicationFiled: July 31, 2015Publication date: September 14, 2017Inventors: Celine MONNET, Alexandre FONTAYNE
-
Patent number: 9551009Abstract: A transcription unit constituted by a polynucleotide including the hCMVie virus enhancer, the enhancer having the nucleotide sequence SEQ ID NO: 1, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 1 and essentially having transcription activation properties, and the promoter region of Cyclin-Dependent Kinase 9 (CDK9), the promoter region having the nucleotide sequence SEQ ID NO: 2, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 2 and essentially having a promoter activity.Type: GrantFiled: October 29, 2012Date of Patent: January 24, 2017Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Alexandre Fontayne, Francois Coutard
-
Patent number: 9512230Abstract: Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.Type: GrantFiled: February 8, 2013Date of Patent: December 6, 2016Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Alexandre Fontayne, Francois Coutard
-
Publication number: 20160177286Abstract: The present invention relates to a protein consisting of the sequence SEQ ID No.: 11 or 25 or 26, directly bound, or bound via a linker, especially -Arg-Lys-Arg-, to the sequence SEQ ID No.: 6.Type: ApplicationFiled: June 20, 2014Publication date: June 23, 2016Applicants: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS, UNIVERSITE GRENOBLE I JOSEPH FOURIERInventors: Aline Thomas, Marie-Claire Dagher, Raphael Marlu, Benoit Polack, Jean-Luc Plantier, Alexandre Fontayne, Toufik Abache
-
Publication number: 20150072368Abstract: Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.Type: ApplicationFiled: February 8, 2013Publication date: March 12, 2015Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Alexandre Fontayne, François Coutard
-
Publication number: 20140378663Abstract: A method for producing a variant of a parent polypeptide including a Fc region, which variant exhibits reduced binding to the protein C1q and to at least one receptor Fcg? R as compared to the parent polypeptide.Type: ApplicationFiled: June 25, 2012Publication date: December 25, 2014Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DE BIOTECHNOLOGIESInventors: Alexandre Fontayne, Sylvie Jorieux, Celine Monnet-Mars, Philippe Mondon, Abdelhakim Kharrat, Khalil Bouayadi
-
Patent number: 8883450Abstract: A use of a signal peptide for producing a recombinant polypeptide of interest in an expression system, the signal peptide includes at least 12 amino acids of formula (I): (X1)iX2X3X4SX5X6X7, wherein: X1 is a peptide containing from 3 to 6 amino acids, i equal to 0 or 1, X2 is a peptide containing from 3 to 9 hydrophobic amino acids, X3 is a peptide containing from 3 to 5 amino acids, the peptide including at least 3 contiguous or non-contiguous leucines X4 is a peptide containing from 2 to 5 amino acids chosen from Ala, Thr, Ser, Gln, Ile, Met, X5 is Ala or Val, X6 is Gln, Asn or His, X7 is Ala or Cys, provided that when the signal peptide originates from a natural precursor of a specific protein, the polypeptide of interest is different from the protein.Type: GrantFiled: March 17, 2011Date of Patent: November 11, 2014Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventor: Alexandre Fontayne
-
Publication number: 20140242638Abstract: A transcription unit constituted by a polynucleotide including the hCMVie virus enhancer, the enhancer having the nucleotide sequence SEQ ID NO: 1, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 1 and essentially having transcription activation properties, and the promoter region of Cyclin-Dependent Kinase 9 (CDK9), the promoter region having the nucleotide sequence SEQ ID NO: 2, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 2 and essentially having a promoter activity.Type: ApplicationFiled: October 29, 2012Publication date: August 28, 2014Inventors: Alexandre Fontayne, Francois Coutard
-
Publication number: 20140050722Abstract: A chimeric monoclonal antibody targeted to ricin is presented. The light chain and heavy chain constant regions are respectively made up of the light chain and heavy chain constant regions of human immunoglobulin, and the light chain and heavy chain variable regions respectively include the light chain and heavy chain variable regions of macaque immunoglobulin. The antibody does not substantially induce any immune response against chimeric antibodies.Type: ApplicationFiled: August 15, 2013Publication date: February 20, 2014Applicants: LFB BIOTECHNOLOGIES, ETAT FRANCAIS REPRESENTE PAR LE DELEGUE GENERAL POUR L'ARMEMENTInventors: Philippe THULLIER, Alexandre FONTAYNE
-
Patent number: 8535668Abstract: A chimeric monoclonal antibody targeted at ricin, in which the light chain and heavy chain are such that: the constant region of the light chain and the constant region of the heavy chain are essentially made up respectively of the constant region of the light chain and the constant region of the heavy chain of human immunoglobulin, the variable region of the light chain and the variable region of the heavy chain include respectively the variable region of the light chain and the variable region of the heavy chain of macaque immunoglobulin, the monoclonal antibody not substantially inducing an immune response against chimeric antibodies.Type: GrantFiled: November 4, 2010Date of Patent: September 17, 2013Assignees: Etat Francais Represente par le Delegue General pour l'Armement, LFB BiotechnologiesInventors: Philippe Thullier, Alexandre Fontayne
-
Publication number: 20130122546Abstract: A use of a signal peptide for producing a recombinant polypeptide of interest in an expression system, the signal peptide includes at least 12 amino acids of formula (I): (X1)iX2X3X4SX5X6X7, wherein: X1 is a peptide containing from 3 to 6 amino acids, i equal to 0 or 1, X2 is a peptide containing from 3 to 9 hydrophobic amino acids, X3 is a peptide containing from 3 to 5 amino acids, the peptide including at least 3 contiguous or non-contiguous leucines X4 is a peptide containing from 2 to 5 amino acids chosen from Ala, Thr, Ser, Gln, Ile, Met, X5 is Ala or Val, X6 is Gln, Asn or His, X7 is Ala or Cys, provided that when the signal peptide originates from a natural precursor of a specific protein, the polypeptide of interest is different from the protein.Type: ApplicationFiled: March 17, 2011Publication date: May 16, 2013Applicant: LFB BIOTECHNOLOGIESInventor: Alexandre Fontayne